Zhitong Financial APP learned that the transcatheter aortic valve repair system-Leaflex aortic valve Performer (hereinafter referred to as "Leaflex valve") introduced by Qiming Medical-B (02500) completed its first human application in China on October 17th. As of 10:52, it was up 4.37% to quote HK $35.80, with a turnover of 63.9618 million.

The application of this example was carried out successfully by Professor Dong Nianguo of Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, with the cooperation of Professor Wu Yongjian of Fuwai Hospital of Chinese Academy of Medical Sciences, Professor Peng Xiaoping and Professor Jiang Yu of the first affiliated Hospital of Nanchang University.

It is worth mentioning that the operation is also combined with the use of another innovative device of Qiming Medical, the TriGUARD3 antithrombotic distal brain protection device (hereinafter referred to as "TriGUARD3 brain"). This opens a precedent for the clinical use of China's first mechanized non-implanted heart valve calcification repair system and the first distal brain protective device.

The treatment achieved the desired effect, the patient's hemodynamics was stable, the whole repair process did not need to be carried out under the condition of pacing, and the aortic regurgitation was not aggravated after the repair. TEE showed that the peak flow velocity of the valve decreased by 37.4%, the peak pressure difference decreased by 58.9%, and the average pressure difference decreased by 56.4%. The innovative combination of TriGUARD3 drugs can effectively prevent embolic materials that may fall into the brain during the operation, reduce the risk of cerebral embolism, and further improve the safety of the operation. The patient recovered well after operation and was discharged on October 27.